No association of the NFKB1 insertion/deletion promoter polymorphism with survival in patients with gastric cancer

Japanese Journal of Clinical Oncology

Volumn 39, Issue 8, 2009, Pages 497-501

  Kim, Jong Gwang ^a   Sohn, Sang Kyun ^a   Chae, Yee Soo ^a   Moon, Joon Ho ^a   Kim, Shi Nae ^a   Kang, Byung Woog ^a   Kim, Gab Chul ^a   Lee, Myung Hoon ^a   Jeon, Seong Woo ^a   Chung, Ho Young ^a   Yu, Wansik ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Gastric cancer; NFKB1; Polymorphism; Prognosis

Indexed keywords

FLUOROURACIL; GENOMIC DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; DNA; NFKB1 PROTEIN, HUMAN;

ADULT; AGED; ALLELE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA EXTRACTION; FEMALE; GENE DELETION; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; STOMACH ADENOCARCINOMA; STOMACH CANCER; ADENOCARCINOMA; FEASIBILITY STUDY; GENE EXPRESSION REGULATION; GENETICS; KOREA; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH TUMOR; SURVIVAL RATE; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA, NEOPLASM; FEASIBILITY STUDIES; FEMALE; GENE DELETION; HUMANS; KOREA; MALE; MIDDLE AGED; MUTAGENESIS, INSERTIONAL; NEOPLASM STAGING; NF-KAPPA B P50 SUBUNIT; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 68849086682     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp056     Document Type: Article

References (20)

1. Kim JP, Hur YS, Choe KJ. Clinical analysis of 1136 early gastric cancers. Cancer Res Treat 1993;25:808-18.
2. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
3. Gonzalez CA, Sala N, Capella G. Genetic susceptibility and gastric cancer risk. Int J Cancer 2002;100:249-60.
4. Chen F, Castranova V, Shi X, Demers LM. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of disease. Clin Chem 1999;45:7-17.
5. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004;13:35-45.
6. Rueda B, Nunez C, Lopez-Nevot MA, Paz Ruiz M, Urcelay E, De la Concha EG, et al. Functional polymorphism of the NFKB1 gene promoter is not relevant in predisposition to celiac disease. Scand J Gastroenterol 2006;41:420-3.
7. Oliver J, Gomez-Garcia M, Paco L, Lopez-Nevot MA, Pinero A, Correro F, et al. A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm Bowel Dis 2005;11:576-9.
8. Lin SC, Liu CJ, Yeh WI, Lui MT, Chang KW, Chang CS. Functional polymorphism in NFKB1 promoter is related to the risks of oral squamous cell carcinoma occurring on older male areca (betel) chewers. Cancer Lett 2006;243:47-54.
9. Zhou B, Rao L, Li Y, Gao L, Wang Y, Chen Y, et al. A functional insertion/deletion polymorphism in the promoter region of NFKB1 gene increases susceptibility for nasopharyngeal carcinoma. Cancer Lett 2009;275:72-6.
10. Riemann K, Becker L, Struwe H, Rübben H, Eisenhardt A, Siffert W. Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer. Int J Clin Pharmacol Ther 2007;45:423-30.
11. Riemann K, Becker L, Struwe H, Nuckel H, Duhrsen U, Alakus H, et al. No association of the NFKB1 insertion/deletion promoter polymorphism with survival in colorectal and renal cell carcinoma as well as disease progression in B-cell chronic lymphocytic leukemia. Pharmacogenet Genomics 2006;16:783-8.
12. Hamilton SR, Aaltonen LA. WHO Classification. Tumours of the Digestive System: Pathology and Genetics. Lyon, France: IARC Press 2000.
13. Greene FL, Page DL, Fleming ID. The AJCC Cancer Staging Manual. 6th edn. New York: Springer 2002.
14. Yang J, Pan WH, Clawson GA, Richmond A. Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth. Cancer Res 2007;67:3127-34.
15. Criswell TL, Arteaga CL. Modulation of NFkappaB activity and E-cadherin by the type III transforming growth factor beta receptor regulates cell growth and motility. J Biol Chem 2007;282: 32491-500.
16. Loercher A, Lee TL, Ricker JL, Howard A, Geoghegen J, Chen Z, et al. Nuclear factor-kappa B is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64:6511-23.
17. Li H, Gao L, Shen Z, Li CY, Li K, Lv YJ, et al. Association study of NFKB1 and SUMO4 polymorphisms in Chinese patients with psoriasis vulgaris. Arch Dermatol Res 2008;300:425-33.
18. Lo SS, Chen JH, Wu CW, Lui WY. Functional polymorphism of NFKB1 promoter may correlate to the susceptibility of gastric cancer in aged patients. Surgery 2009;145:280-5.
19. Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet 2005;32:401-5.
20. Bu H, Rosdahl I, Sun XF, Zhang H. Importance of polymorphisms in NF-kappaB1 and NF-kappaB1alpha genes for melanoma risk, clinicopathological features and tumor progression in Swedish melanoma patients. J Cancer Res Clin Oncol 2007;133:859-66.